CardioComm Solutions, Inc. (EKGGF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
CardioComm Solutions, Inc. (EKGGF) trades at $0.0109. CardioComm Solutions, Inc. specializes in developing software and hardware for electrocardiogram (ECG) and ambulatory arrhythmia monitoring systems. Market cap: $2.15M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for EKGGF: EKGGF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates EKGGF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
EKGGF: 2/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →CardioComm Solutions, Inc. (EKGGF) Healthcare & Pipeline Overview
CardioComm Solutions, Inc., based in Canada, provides ECG and arrhythmia monitoring solutions, including software and hardware for medical and consumer applications. The company's Global ECG Management System (GEMS) and HeartCheck devices support arrhythmia screening, diagnosis, and cardiac patient management, positioning them in the healthcare information services sector.
What Is the Investment Thesis for EKGGF?
CardioComm Solutions, Inc. presents a focused investment opportunity within the healthcare information services sector, driven by its proprietary ECG technology and diverse product portfolio. The company's Global ECG Management System (GEMS) and HeartCheck devices cater to both medical professionals and consumers, addressing the growing demand for accessible cardiac monitoring solutions. Growth catalysts include expanding telemedicine applications and strategic partnerships to broaden market reach. However, potential risks include competition from larger medical device companies and the need for continuous innovation to maintain technological superiority. With a gross margin of 89.5%, CardioComm demonstrates strong potential for profitability if revenue scales effectively. Investors should monitor the company's ability to secure regulatory approvals and expand its market share in key geographic regions.
Based on FMP financials and quantitative analysis
EKGGF Key Highlights
Gross margin of 89.5% indicates strong potential profitability from core operations.
- Negative P/E ratio of -3.05 reflects current losses, highlighting the need for revenue growth and cost management.
- Beta of -2.23 suggests the stock is less volatile than the market, but also indicates potential underperformance during market upswings.
- The company's focus on ECG and arrhythmia monitoring aligns with the increasing prevalence of cardiovascular diseases globally.
- Proprietary device connectivity and ECG management technologies offer a competitive edge in the telemedicine and remote patient monitoring markets.
Who Are EKGGF's Competitors?
EKGGF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| DTRK DATATRAK International, Inc. | $0.29 | +0.00% | $8.28M | 47 |
| CMHSF Comprehensive Healthcare Systems, Inc. | $0.31 | +0.00% | $5.62M | 55 |
| CRBKF Carebook Technologies Inc. | $0.03 | +0.00% | $6.84M | 64 |
| CMPD CompuMed, Inc. | $7.25 | -7.70% | $9.35M | 60 |
| BBLN Babylon Holdings Limited | $0.55 | -13.99% | $14.1M | 56 |
| THKKF Think Research Corporation | $0.23 | -1.74% | $17.8M | 57 |
| AKLI Akili, Inc. | $0.43 | +0.25% | $34.1M | 67 |
| AIRDF Rocket Doctor AI Inc. | $0.44 | -2.99% | $42.4M | 56 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are EKGGF's Key Strengths?
Proprietary ECG technology and software solutions.
- Diverse product portfolio catering to medical and consumer markets.
- Established presence in the ECG monitoring market.
- Integration with EMR systems.
What Are EKGGF's Weaknesses?
Limited financial resources compared to larger competitors.
- Dependence on regulatory approvals for new products.
- Negative P/E ratio indicates current losses.
- OTC market listing limits access to capital.
What Could Drive EKGGF Stock Higher?
Expansion into telemedicine and remote patient monitoring markets.
- Strategic partnerships with healthcare providers and distributors.
- Potential regulatory approvals for new products and technologies.
- Development and integration of AI-powered diagnostic tools.
- Direct-to-consumer marketing initiatives to promote HeartCheck devices.
What Are the Key Risks for EKGGF?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Competition from larger medical device companies with greater resources.
- Technological obsolescence and the need for continuous innovation.
- Changes in healthcare regulations affecting ECG monitoring and telemedicine.
- Limited financial resources compared to competitors.
- Dependence on key personnel and strategic partnerships.
What Are the Growth Opportunities for EKGGF?
- Expansion into Telemedicine: The growing telemedicine market presents a significant opportunity for CardioComm. By integrating its ECG monitoring solutions with telemedicine platforms, CardioComm can reach a broader patient base and provide remote cardiac care services. The global telemedicine market is projected to reach $431.82 billion by 2030, growing at a CAGR of 25.9% from 2023. CardioComm can capitalize on this trend by partnering with telemedicine providers and developing integrated solutions that enhance remote patient monitoring capabilities. Timeline: Ongoing.
- Strategic Partnerships with Healthcare Providers: Collaborating with hospitals, clinics, and other healthcare providers can drive adoption of CardioComm's ECG monitoring solutions. By offering integrated solutions that streamline cardiac care workflows, CardioComm can establish long-term partnerships and secure recurring revenue streams. These partnerships can also facilitate access to patient data and enable the development of more targeted and effective cardiac monitoring solutions. Timeline: Ongoing.
- Geographic Expansion: Expanding into new geographic markets, particularly in developing countries with limited access to cardiac care, represents a significant growth opportunity for CardioComm. By adapting its products and services to meet the specific needs of these markets, CardioComm can tap into a large and underserved patient population. This expansion requires strategic partnerships with local distributors and healthcare providers to navigate regulatory requirements and establish a strong market presence. Timeline: Ongoing.
- Development of AI-Powered Diagnostic Tools: Integrating artificial intelligence (AI) into its ECG monitoring solutions can enhance diagnostic accuracy and efficiency. By developing AI-powered algorithms that analyze ECG data and identify potential cardiac abnormalities, CardioComm can provide healthcare providers with valuable insights and improve patient outcomes. The AI in healthcare market is projected to reach $194.4 billion by 2030, growing at a CAGR of 37.7% from 2023. Timeline: Upcoming.
- Direct-to-Consumer Marketing: CardioComm can leverage direct-to-consumer marketing to promote its HeartCheck devices and other consumer-focused ECG monitoring solutions. By targeting individuals at risk of cardiac events, CardioComm can drive adoption of its products and empower consumers to take control of their heart health. This marketing strategy requires a strong online presence and effective communication of the benefits of regular ECG monitoring. Timeline: Ongoing.
What Are EKGGF's Competitive Advantages?
- Proprietary ECG management software (GEMS).
- Established presence in the ECG monitoring market.
- Integration with EMR systems.
- Handheld ECG monitoring devices (HeartCheck).
What Does EKGGF Do?
CardioComm Solutions, Inc., established in 1989 and headquartered in Toronto, Canada, focuses on developing and delivering advanced software and hardware solutions for electrocardiogram (ECG) and ambulatory arrhythmia monitoring. The company's core business revolves around its proprietary technology used in products designed for the recording, transmission, viewing, analyzing, reporting, and storage of ECGs. These products serve a broad range of applications, including arrhythmia screening, diagnosis, and management of cardiac patients. CardioComm's key offerings include the Global ECG Management System (GEMS), a comprehensive software solution for cardiac event monitoring, and the GlobalCardio 12 Lead, a web-enabled ECG device that integrates with Electronic Medical Records (EMR) systems. The company also provides handheld ECG monitors under the HeartCheck brand, including the HeartCheck PEN and HeartCheck devices, along with Sirona telephonic and wireless event recorders. CardioComm's solutions extend to various sectors, including medical, consumer, clinical research, and telemedicine, reflecting its commitment to providing versatile and accessible cardiac monitoring technologies. The company's ASP services, such as C4 ECG management services and HeartCheck SMART Monitoring, further enhance its service offerings, solidifying its position in the global market for ECG and arrhythmia monitoring solutions.
What Products and Services Does EKGGF Offer?
- Develops ECG and ambulatory arrhythmia monitoring systems.
- Offers software solutions for cardiac event monitoring (GEMS).
- Provides web-enabled ECG devices compatible with EMR systems.
- Manufactures handheld ECG monitors (HeartCheck PEN and HeartCheck).
- Offers telephonic and wireless event recorders (Sirona).
- Provides ASP services, including ECG management and SMART Monitoring.
- Develops software modules for wireless ECG monitoring and EMR integration.
How Does EKGGF Make Money?
- Software licensing for GEMS and related modules.
- Hardware sales of HeartCheck devices and Sirona recorders.
- Subscription-based ASP services for ECG management and monitoring.
- Partnerships with healthcare providers and telemedicine platforms.
What Industry Does EKGGF Operate In?
CardioComm Solutions, Inc. operates within the healthcare information services sector, which is experiencing growth due to the increasing prevalence of cardiovascular diseases and the rising demand for remote patient monitoring solutions. The market is competitive, with established medical device companies and emerging technology firms vying for market share. CardioComm's focus on ECG and arrhythmia monitoring positions it within a niche segment of the broader healthcare IT market. The company's success depends on its ability to innovate, secure regulatory approvals, and establish strategic partnerships to expand its market reach.
Who Are EKGGF's Key Customers?
- Hospitals and clinics.
- Cardiologists and other healthcare professionals.
- Clinical research organizations.
- Individual consumers at risk of cardiac events.
Company Profile
CardioComm Solutions, Inc. operates in the Medical - Healthcare Information Services industry within the Healthcare sector. It is headquartered in Toronto, CA. The company is led by CEO Etienne Grima. EKGGF has traded publicly since 2010.
Financial Health
CardioComm Solutions, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Key Financial Metrics
Return on equity for CardioComm Solutions, Inc. stands at 103.3%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -35.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.17 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -39.4%, the inverse of the P/E and a quick read on earnings relative to price.
EKGGF Valuation & Market Position
With a $2.15M market cap, CardioComm Solutions, Inc. sits in the micro-cap segment of the market.
EKGGF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Proprietary ECG technology and software solutions.
- Diverse product portfolio catering to medical and consumer markets.
- Established presence in the ECG monitoring market.
- Integration with EMR systems.
Bear Case
- Limited financial resources compared to larger competitors.
- Dependence on regulatory approvals for new products.
- Negative P/E ratio indicates current losses.
- OTC market listing limits access to capital.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
EKGGF Latest News
No recent news available for EKGGF.
EKGGF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for EKGGF.
Price Targets
Wall Street price target analysis for EKGGF.
EKGGF MoonshotScore
What does this score mean?
The MoonshotScore rates EKGGF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Etienne Grima
Unknown
Information about Etienne Grima's background is not available in the provided data. Therefore, a comprehensive biography cannot be constructed. Further research would be required to ascertain his career history, education, and previous roles.
Track Record: Information about Etienne Grima's track record is not available in the provided data. Therefore, a detailed assessment of his achievements, strategic decisions, and company milestones under his leadership cannot be provided. Further research would be required to evaluate his performance.
EKGGF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that CardioComm Solutions, Inc. may not meet the minimum financial standards required for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited reporting requirements and may not be subject to the same level of scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. This tier often includes companies with distressed financials, early-stage ventures, or those that choose not to meet the listing requirements of higher tiers. Investors should exercise caution and conduct thorough due diligence before investing in companies on the OTC Other tier.
- OTC Tier: OTC Other
- Limited financial disclosure requirements increase information asymmetry.
- Lower liquidity can lead to price volatility and difficulty in trading shares.
- Higher risk of fraud or mismanagement compared to companies on major exchanges.
- Limited regulatory oversight increases the potential for market manipulation.
- OTC Other tier companies may have distressed financials or unproven business models.
- Verify the company's financial statements and SEC filings (if available).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's liquidity and trading volume.
- Review any legal or regulatory issues involving the company.
- Consult with a financial advisor before investing.
- Understand the risks associated with investing in OTC stocks.
- The company has been in operation since 1989.
- CardioComm has developed proprietary ECG technology and software solutions.
- The company's products are used in medical, consumer, clinical research, and telemedicine applications.
- CardioComm has established partnerships with healthcare providers.
Common Questions About EKGGF (Healthcare)
What does CardioComm Solutions, Inc. do?
CardioComm Solutions, Inc. specializes in the development and commercialization of advanced software and hardware solutions for electrocardiogram (ECG) and ambulatory arrhythmia monitoring. Their core offerings include the Global ECG Management System (GEMS), a software platform for cardiac event monitoring, and HeartCheck devices, handheld ECG monitors for both medical professionals and consumers.
What are the key growth opportunities for EKGGF in healthcare?
CardioComm Solutions, Inc. has several growth opportunities within the healthcare sector. These include expanding its telemedicine applications to capitalize on the increasing demand for remote patient monitoring, forging strategic partnerships with healthcare providers to integrate its ECG solutions into clinical workflows, and expanding geographically into underserved markets.
What are the main risks for EKGGF?
CardioComm Solutions, Inc. faces several risks, including competition from larger medical device companies with greater financial and marketing resources. The company also faces the risk of technological obsolescence, requiring continuous innovation to maintain its competitive edge. Changes in healthcare regulations, particularly those affecting ECG monitoring and telemedicine, could also impact the company's business.
What are the key factors to evaluate for EKGGF?
Evaluate EKGGF on fundamentals, analyst consensus, and risk factors. CardioComm Solutions, Inc. presents a focused investment opportunity within the healthcare information services sector, driven by its proprietary ECG technology and diverse product portfolio. Not financial advice.
How frequently does EKGGF data refresh on this page?
EKGGF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven EKGGF's recent stock price performance?
CardioComm Solutions, Inc. (EKGGF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary ECG technology and software solutions. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider EKGGF overvalued or undervalued right now?
CardioComm Solutions, Inc. (EKGGF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research EKGGF before investing?
Before investing in CardioComm Solutions, Inc. (EKGGF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is limited, and the OTC listing adds inherent risks.
- AI analysis is pending, which could provide further insights.